BLA 125268 · Amgen
Nplate
Romiplostim · Subcutaneous · Thrombopoietin Receptor Agonist
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Aug 22, 2008
Approved uses
4
Original approval plus efficacy supplements
Registered trials
105
26 Phase 3, 19 recruiting
FAERS reports
15,183
11,695 serious, 2,656 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 23, 2026.
Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) 1.1 Patients with Immune Thrombocytopenia (ITP) Nplate is indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. 1.2 Patients with Hematopoietic Syndrome of Acute Radiation Syndrome Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation [see Clinical Studies (14.3) ] . Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to...
Mechanism: Nplate increases platelet production through binding and activation of the TPO receptor, a mechanism analogous to endogenous TPO.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 28, 2021 Supplement 167 · Efficacy · priority review OrphanLabelLetterReview
- Oct 17, 2019 Supplement 164 · Efficacy OrphanLabelLetter
- Dec 14, 2018 Supplement 163 · Efficacy · priority review OrphanLabelLetter
- Aug 22, 2008 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanSummary ReviewLabelReview
1 products under this application
- NPLATE · ROMIPLOSTIM 250MCG/0.5ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Romiplostim" as an intervention, any sponsor and status, largest first.
- Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective ProcedureStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04915287 · 476 participants (planned) · Start Jun 6, 2021 · Primary completion Jun 30, 2023
Drug: Avatrombopag maleate; Platelet transfusion and 1 more · For: Thrombocytopenia; Drugs; Chronic Liver Disease
Sites: Beijing, China
- Immune Thrombocytopenia Management in AdultsPivotal-lookingStatus unknown
Nahda UniversityAcademic, hospital or other
NCT05861297 · 467 participants (planned) · Start May 5, 2020 · Primary completion Jan 18, 2024
Drug: Dexamethasone; Prednisolone and Azathioprine and 3 more · For: Immune Thrombocytopenia Purpura
Sites: Cairo, Egypt
- An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITPPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00508820 · 407 participants · Start Feb 1, 2005 · Primary completion Jan 1, 2011
Drug: Romiplostim · For: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenic Purpura
- Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00116688 · 313 participants · Start Aug 2004 · Primary completion Jan 2010
Drug: Romiplostim · For: Thrombocytopenia; Idiopathic Thrombocytopenic Purpura
- A Multicenter Clinical Study of Romiplostim N01 in the Treatment of Sepsis-related ThrombocytopeniaPivotal-lookingNot yet recruiting
Shanghai 10th People's HospitalAcademic, hospital or other
NCT07595133 · 280 participants (planned) · Start Jun 1, 2026 · Primary completion Dec 31, 2027
Drug: Administer Romiplostim treatment.; Administer recombinant human thrombopoietin therapy · For: Sepsis
- Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00614523 · 250 participants · Start Jul 21, 2008 · Primary completion Mar 31, 2011
Drug: Placebo; Romiplostim · For: MDS; Myelodysplastic Syndromes; Thrombocytopenia
- Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic PurpuraPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00415532 · 234 participants · Start Dec 1, 2006 · Primary completion Nov 7, 2008
Drug: Medical Standard of Care for ITP; Romiplostim · For: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) and 1 more
- Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid TumorsPivotal-lookingRecruiting
Peking University People's HospitalAcademic, hospital or other
NCT07586826 · 220 participants (planned) · Start Dec 22, 2025 · Primary completion Oct 31, 2027
Drug: Romiplostim N01; All-trans retinoic acid · For: Persistent Isolated Chemotherapy-Induced Thrombocytopenia; Chemotherapy-Induced Thrombocytopenia; Gynecologic Cancers and 7 more
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- platelet count decreased1,778
- drug ineffective1,768
- off label use1,282
- thrombocytopenia1,048
- death1,016
- platelet count abnormal962
- therapeutic response decreased942
- headache616
- fatigue478
- platelet count increased404
- hospitalisation393
- haemorrhage391
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 47 |
| 2009 | 410 |
| 2010 | 1,850 |
| 2011 | 2,054 |
| 2012 | 891 |
| 2013 | 527 |
| 2014 | 630 |
| 2015 | 799 |
| 2016 | 616 |
| 2017 | 982 |
| 2018 | 1,124 |
| 2019 | 612 |
| 2020 | 522 |
| 2021 | 536 |
| 2022 | 605 |
| 2023 | 826 |
| 2024 | 790 |
| 2025 | 687 |
| 2026 | 675 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: NPlate (Romiplostim)
2024 spending
$17.6M
Beneficiaries
285
1,734 claims
Per beneficiary
$61,839
$2,809.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,765,856 |
| 2021 | $11,537,407 |
| 2022 | $13,219,386 |
| 2023 | $13,864,764 |
| 2024 | $17,623,974 |
Part B: NPlate (Romiplostim) · HCPCS J2796
2024 spending
$362M
Beneficiaries
6,523
92,588 claims
Per beneficiary
$55,572
2024 ASP limit $98.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $232,041,197 |
| 2021 | $248,357,392 |
| 2022 | $283,987,979 |
| 2023 | $323,220,820 |
| 2024 | $362,499,336 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.
Al-Samkari H, Muñoz C, Geredeli Ç, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Multicenter Study
- Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Soff GA, Miao Y, Bendheim G, et al. · J Clin Oncol 2019 · Clinical Trial, Phase II, Randomized Controlled Trial
- Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.
Jang JH, Tomiyama Y, Miyazaki K, et al. · Br J Haematol 2021 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.
Gurumurthy G, Kisiel F, Gurumurthy S, et al. · J Oncol Pharm Pract 2025 · Meta-Analysis
- Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis.
Zhang X, Zhao Y, Yang M, et al. · Front Immunol 2025 · Comparative Study, Network Meta-Analysis
- Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
Kuter DJ, Bussel JB, Lyons RM, et al. · Lancet 2008 · Multicenter Study, Randomized Controlled Trial
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.